Physician

Eva Gupta, MD

According to 2025 Medicare claims, Eva Gupta, MD (NPI: 1093944092) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Pasco, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33543-7504.

Gupta's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 599 traditional Medicare patients, billed 188,950 HCPCS/CPT codes, and received $2,077,000 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 995 prescription claims across 251 beneficiaries totaling $3,393,598 in drug costs, led by Revlimid (Lenalidomide). Open Payments data shows 209 records totaling $5,413. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $4,708 to $2,077,000. Similarly, Part D prescription costs have moved sharply higher in recent years, from $80,278 to $3,393,598. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	56	62	$4,708
2016	146	244	$17,041
2017	356	1,060	$97,900
2018	428	2,151	$131,033
2019	459	13,680	$208,452
2020	273	93,429	$1,084,965
2021	332	110,494	$1,308,964
2022	382	164,619	$1,933,142
2023	482	163,300	$1,890,931
2024	599	188,950	$2,077,000

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	42	133	$80,278
2016	27	61	$8,387
2017	13	24	$676
2018	N/R	N/R	N/R
2019	14	29	$2,022
2020	82	315	$221,677
2021	137	503	$649,180
2022	168	808	$1,914,722
2023	220	975	$2,160,624
2024	251	995	$3,393,598

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	350	917	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	169	226	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	189	338	$13
36415	Insertion of needle into vein for collection of blood sample	408	1,164	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	408	1,196	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	45	1,260	$768,324
Jakafi	Ruxolitinib Phosphate	24	720	$622,227
Calquence	Acalabrutinib Maleate	41	1,230	$612,132
Xtandi	Enzalutamide	26	780	$357,699
Tagrisso	Osimertinib Mesylate	17	510	$282,242

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	209	$5,413	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Eva Gupta, MD?

Tedicare shows public-source Medicare data for Eva Gupta, MD (NPI 1093944092), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Eva Gupta, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Eva Gupta, MD?

Eva Gupta, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Eva Gupta, MD have Open Payments data?

Eva Gupta, MD has 209 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.